Oncolytic viruses (OVs) are a class of viruses that can selectively replicate in and lyse cancer cells, and subsequent spread with a tumor while not causing damage to normal cells. Besides the direct oncolytic activity, OVs are also effective in stimulating the body immune responses which can further help recogonize, control or destroy cancer cells. Through the combination of the tumor-specific cell lysis and immune stimulation, OVs act their antitumor activities in situ.
OVs encompass a broad diversity of DNA and RNA viruses, typically fall into 2 classes: 1) viruses that are naturally cancer-selective such as reovirus, 2) viruses that are genetically-manipulated including measles virus, adenovirus and herpes simplex virus (HSV-1) and so on.
To date, the effectiveness of OVs has been supported by many preclinical data. A few of oncolytic viruses has been approved by FDA in the United States. The OV approach to cancer treatment is becoming more interesting for scientists.
Creative Biogene offers premade oncolytic viruses including Measles Virus (MeV) and Herpes Simplex Virus (HSV-1) for promoting oncolytic studies.
Premade Oncolytic Virus Products List